Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B‐Cell Levels Do Not Correlate With Clinical Response

Abstract

This study characterized the relationship between clinical response, serum rituximab concentrations, and peripheral B-cell levels in patients with rheumatoid arthritis treated with rituximab. Data were analyzed from a double-blind, phase IIa trial in which 161 patients with active rheumatoid arthritis despite continuing methotrexate were randomized to methotrexate alone (10-25 mg/wk), rituximab alone (single course: 1000 mg administered intravenously on days 1 and 15), rituximab plus cyclophosphamide (750 mg administered intravenously on days 3 and 17), or rituximab plus methotrexate. Serum samples for pharmacokinetic analysis were collected through 24 weeks, and peripheral circulating CD19+ B-cell levels were measured through 48 weeks. All treatments were generally well tolerated, with no clinically relevant excess of adverse events leading to withdrawal among patients who received rituximab compared with those who received methotrexate alone. The proportions of patients who achieved an American College of Rheumatology score of 50 at week 24 were 13% (methotrexate alone), 33% (rituximab alone), 41% (rituximab plus cyclophosphamide), and 43% (rituximab plus methotrexate). Peripheral B-cell depletion occurred by day 15 in all patients treated with rituximab. There was no relationship between B-cell depletion and clinical response. Recovery of peripheral B cells was variable and showed no relationship with return of disease activity in patients who responded to rituximab. The mean terminal half-life of rituximab was 19 to 22 days; pharmacokinetic parameters were similar whether rituximab was administered alone or with methotrexate or cyclophosphamide. Because the level of peripherally circulating B cells does not appear to correlate with a maintained clinical response in patients with rheumatoid arthritis, the timing of rituximab retreatment should be based on clinical symptoms rather than peripheral B-cell levels.

Humoral-Targeted Immunotherapies in Multiple Sclerosis

“…The recovery of peripheral B cells in patients with MS was variable and showed no association with return of disease activity. This dissociation was also noted in RA trials [25,26,33].…”

Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab

“…We focused our study on patients who were within 5-24 months of receiving rituximab therapy, when patients exhibited disease remission and the B cell compartment was numerically reconstituted, either partially or fully ( Figure 1A). Based on pharmacokinetic data for rituximab (12), we expect little rituximab to remain in circulation at this point, which would be important for interpretation. Overall, the frequency of peripheral B cells, defined as CD3 -…”

“…Thus, it has little effect on preexisting serum antibody titers produced by long-lived plasma cells, such as antibodies against childhood vaccines, including tetanus or meningitis (6,10), but completely eliminates peripheral B cell memory. Depletion of peripheral B cells typically lasts for 6-9 months, with numbers recovering after 1 year (12). Despite recovery of total B cell numbers, the repopulated B cell compartment consists largely of naive cells, and total memory B cells (MBCs) remain almost absent in peripheral blood, even 5 years after treatment (13).…”

Factors Associated with Severe Skin Infections in Patients Treated with Biologic Therapies for Inflammatory Rheumatic Diseases

“…The terminal elimination half-life of etanercept is shorter (5 days) [30], but the duration of response can reach 3 months, suggesting a possible maintenance of the immune effect after terminal elimination [34]. The mean terminal elimination half-life of rituximab is 3 weeks, but the mean B cell lymphocyte depletion duration is 12 months [25,35]. …”